Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 44 for “"immune checkpoint inhibitors"”.
-
Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors
… has been shown to induce a secondary anti-tumor immune response through the engagement of T cells. Therefore, the D2C7-IT-induced secondary anti-tumor immune response was investigated using syngeneic mouse glioma models in immunocompetent mice. Moreover, previous studies have demonstrated that …
-
Increased Risk of Cutaneous Immune-Related Adverse Events in Patients Treated with Talimogene Laherparepvec and Immune Checkpoint Inhibitors: A Multi-Hospital Cohort Study
The general metadata -- e.g., title, author, abstract, subject headings, etc. -- is publicly available, but access to the submitted files is restricted to UT Southwestern campus access and/or authorized UT Southwestern users.
-
Discovery of Anti-CD47 Peptides for Cancer Immunotherapy and CD47-mimicking Peptides That Inhibit Phagocytic Clearance of Nanoparticles
… as a standard pillar of cancer treatment. Immune checkpoint inhibitors that are currently available target the adaptive immune system, generating T-cell antitumor responses. As critical innate immune cells, macrophages play important roles in homeostasis, preventing pathogen invasion, …
-
Endocrine Effects of Cancer Chemotherapy
… antitumor antibiotics, targeted therapies, and immune checkpoint inhibitors—affect the endocrine system. It examines chemotherapy-induced dysfunctions in key endocrine glands, including the hypothalamus-pituitary axis, thyroid, adrenal glands, gonads, and pancreas. Special attention is given to …
-
Imaging Biomarkers of Response to Immune Checkpoint Inhibition in Melanoma
Immune checkpoint inhibition using monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1) to enhance cytotoxic T-lymphocyte response against tumours has been used in the management of several malignancies including metastatic melanoma. …
-
Engineered Type 1 Conventional Dendritic Cell–Based Therapies for In Situ Cancer Immunization
Cancer immunotherapy, such as immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T therapy, and cytokine therapy, have achieved successful improvement in extending survival in some patients. However, the immunosuppressive environment of solid tumors substantially compromises therapeutic …
-
Biologically Interpretable Representation Learning for Mechanistic Insights into Cancer Immunotherapy Resistance
Resistance to immune checkpoint inhibitors (ICIs) remains a critical barrier to effective cancer therapy, driven by complex, multi-scale interactions that current biomarkers often fail to capture. This dissertation introduces the Biologically Disentangled Variational Autoencoder (BDVAE)—an …
-
Micrornas Associated With Melanoma Inflammation and Response to Pd-1 Inhibition
… molecularly targeted agents and immunotherapies. Immune checkpoint inhibitors achieve T-cell mediated anti-tumor efficacy by blocking engagement of inhibitory checkpoints on T-cells to overcome immunosuppressive signals from tumor cells and the broader microenvironment. Despite these advances, …
-
Single cell landscape of innate and adaptive immunity in metastatic melanoma treated with immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized the care for cancer and extended survival for many patients. While ICIs have shown astonishing clinical benefits, less than 50% of patients experience a durable response. To find better biomarkers for ICI response and understand the diverse …
-
Investigating the Mechanisms of Resistance to Dual PI3K/MTOR Inhibitor in PIK3CA Mutant Basal Like Bladder Cancer
… to 66%. To date, targeted therapies, except for immune checkpoint inhibitors have not been shown to be effective in the management of this disease, where conventional chemotherapy (i.e. cisplatin) continues to be the standard of care. Therefore, the challenge lies in identifying key molecular …
-
The Role of Ganglioside GD2 and GD3 Synthase (ST8SIA1) in the Regulation of Immune Suppression in Breast Cancer
… gangliosides influence the activity of immune cells including macrophages, NK cells, and T cells. GD3 synthase (GD3S) is the key enzyme that regulates the biosynthesis of the b and c series gangliosides, particularly GD3 and GD2, and studies have shown that GD3S is upregulated in most …
-
Understanding and Targeting The Immunosuppressive Tumor Microenvironment
<p>Immune checkpoint inhibitors (ICIs), such as anti-PD1/PD-L1 and anti-CTLA-4, have shown impressive antitumor efficacy by improving the activity of T cells. While these inhibitors work in many patients with various cancer types, they have minimal or no effect in many more patients. Mounting …
-
Efficacy of novel immunotherapeutic strategies targeting L1CAM in pancreatic cancer
… of cancer contributing to therapy resistance, immune evasion and tumor progression. This study analyzed the therapeutic efficacy of two antibody drug conjugates (ADC) targeting L1CAM with different toxins (monomethyl auristatin E (MMAE) and a pyrrolobenzodiazepine dimer (SG3199)) as payload and …
-
Systems immunology frameworks link multicellular immune perturbation phenotypes and setpoints to response outcomes
… cell technology to understand variation in human immune system response outcomes. We integrate human population, cell subset and single cell variations in molecular phenotypes which give rise to baseline setpoints, are perturbed by vaccination or drug treatment, and are linked to emergent response …
-
Développement d’une méthode d’immuno-imagerie permettant d’évaluer le statut immunitaire des tumeurs
… radiotherapy (RT) and immunotherapy (IT). Immune checkpoint inhibitors have so far yielded only a 15% response rate in unselected patients with squamous cell carcinoma of the head and neck. Imaging the immune microenvironment of the tumor could help guide the selection of patients who might …
-
Development of monoclonal antibodies targeting T cell coinhibitory proteins TIM-3 and TIM-4
Immune checkpoint inhibition (ICI) therapy uses antibodies to block checkpoint proteins from binding with their partner proteins to help overcome dysfunctional T cells and promote the recognition and elimination of tumour cells. The exploration of novel immune checkpoint targets, like T cell …
-
Development of Pharmaceutical Inhibitors Targeting nNOS for Melanoma Treatment
… allowing melanoma cells to escape from immune surveillance. Immune checkpoint inhibitors targeting PD-1/PD-L1 have been shown to prevent immunosuppression and exhibited significant clinical benefits in improving patient survival across a broad range of cancer types including melanoma. Of …
-
The Development of a Cancer-Targeting Peptide-Drug Conjugate for the Treatment of Melanoma
… Within the past decade, eight new targeted and immune checkpoint inhibitors have gained FDA approval. The median life survival has increased significantly from 9 months to over 2 years as a result of this concerted drug development effort; however, this rapid development of treatment …
-
Investigating the Heterogeneity of Tumor Associated Macrophages in Human Hepatocellular Carcinoma
… in treating HCC, such as with the use of novel immune checkpoint inhibitors, the overall response rate remains low. This may be partly attributed to the lack of a clear understanding of the HCC immune microenvironment. However, a high density of regulatory macrophages is correlated with poor …
-
Unravelling the potential applications of extracellular vesicles for the clinical management of melanoma patients
… advanced melanoma, the advent of targeted and immune therapies has substantially improved patient survival. While this is encouraging, further research is needed as the majority of patients treated with targeted therapy ultimately develop drug resistance. Immunotherapy can achieve durable …
Page 1 of 3